Literature DB >> 7529222

Current state of interferon therapy for chronic hepatitis C.

S Iino1, K Hino, K Yasuda.   

Abstract

The current status of interferon (IFN) therapy in chronic hepatitis C is presented, focusing on the results of studies in Japan. Depending on the IFN treatment regimen used in chronic hepatitis C, it is possible to eradicate HCV in a relatively high percentage of patients (about 40%) and to achieve a cure for chronic hepatitis C. The objective of treatment should therefore be the eradication of HCV. The efficacy of IFN in chronic hepatitis C is dependent on the dosage of IFN, duration of treatment, liver histology findings, serum HCV-RNA levels, and HCV genotype. Besides a flu-like syndrome, many adverse reactions are associated with high-dose, long-term IFN treatment. However, as a rule, full recovery or improvement follows prompt withdrawal of IFN. By modification of the IFN, it will be possible to reduce adverse reactions and to create a more effective IFN to further enhance the effect of IFN in chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7529222     DOI: 10.1159/000150362

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  7 in total

Review 1.  Translational control of viral gene expression in eukaryotes.

Authors:  M Gale; S L Tan; M G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

2.  Clinical benefits and cost-effectiveness of 17-year treatment with low-dose interferon-alpha 2b in a patient with chronic hepatitis C: a case report.

Authors:  Takumi Kawaguchi; Shuji Sumie; Minoru Itou; Eitaro Taniguchi; Tsunetaka Matoba; Michio Sata
Journal:  Dig Dis Sci       Date:  2008-07-26       Impact factor: 3.199

3.  Genotypes and virus load in patients with hepatitis C infection.

Authors:  H Hofmann
Journal:  Infection       Date:  1995 May-Jun       Impact factor: 3.553

4.  Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase.

Authors:  M Gale; B Kwieciszewski; M Dossett; H Nakao; M G Katze
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.

Authors:  S J Polyak; S McArdle; S L Liu; D G Sullivan; M Chung; W T Hofgärtner; R L Carithers; B J McMahon; J I Mullins; L Corey; D R Gretch
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Production of infectious HCV genotype 1b virus in cell culture using a novel Set of adaptive mutations.

Authors:  Ken-Ichi Mori; Akihiro Matsumoto; Noboru Maki; Yuki Ichikawa; Eiji Tanaka; Shintaro Yagi
Journal:  BMC Microbiol       Date:  2016-09-27       Impact factor: 3.605

7.  [Implication of mutation of hepatitis C virus 1b interferon sensitivity determining region(NS5A aa 2209-2248) response to interferon alpha therapy in patients with chronic hepatitis C].

Authors:  Z Tang; J Köck; D Moradpour; D Yang; L Hao; H Blum
Journal:  J Tongji Med Univ       Date:  1999
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.